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Abstract 
Background: Iran has achieved a substantial decline in malaria incidence over the past decades. A common feature 
of malaria-endemic settings is the requirement for more sensitive techniques to describe levels of low transmission. In 
this study, serological and parasitological methods were used to measure transmission levels of Plasmodium falci-
parum and Plasmodium vivax during an elimination programme (2012) in Chabahar District, Sistan and Baluchistan 
Province, south-eastern Iran.
Methods: Participants were randomly selected from 64 different geographical clusters in Chabahar city and sur-
rounding villages. Antibody responses to P. falciparum and P. vivax blood-stage antigens were assessed by ELISA, 
while microscopy and molecular testing were used to determine parasite carriage by species. Age-adjusted antibody 
responses were analysed using a reversible catalytic model to calculate seroconversion rates (SCR).
Results: There was no evidence of recent transmission in the study areas, indicated by an absence of parasite infec-
tions in all ages and low or absent serological responses to either species in young children. The best model for age 
P. falciparum seroconversion was one with a change in exposure 21 years before sampling was done in Chabahar city 
(P = 0.018) and 4 years in the villages (P = 0.039). There was a higher level of recent P. vivax transmission compared to 
P. falciparum, based on the SCRs, in both the city and village settings.
Conclusion: Serological analysis identified a decline in P. falciparum transmission in the urban areas of Chabahar, con-
sistent with a previously described decrease in malaria in the early 1990s, demonstrating the utility of this approach 
to reconstruct exposure history. At present, it remains unclear whether the P. vivax antibody responses reflect active 
transmission due to new infections or relapse infections. The absence of parasitological and serological evidence of 
recent malaria transmission in Chabahar District is viable evidence for certification of elimination.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Following global decline in malaria over past decades [1], 
the importance of accurately describing transmission in 
(pre-) elimination areas is widely documented [2]. Use 
of data collected at health facilities might not be robust 
in some areas as data are highly dependent on health-
seeking behaviour and the effectiveness of the health 
system [3]. Evaluating transmission intensity by deter-
mining exposure to malaria-infected mosquitoes is chal-
lenging when mosquito numbers are low [4]. Serological 
evidence of exposure to malaria, by the presence of anti-
malarial antibodies, offers a measure of past infection 
and can determine temporal [5] as well as spatial trends 
in transmission [6]. In low-endemic settings, long-lasting 
antibody responses may be easier to detect than parasite 
carriage in the human population or infected mosqui-
toes. Moreover, the absence of anti-malarial antibodies in 
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certain age groups has been used as evidence of the ces-
sation of transmission in Greece and Mauritius [7, 8]. The 
presence of serological evidence of exposure to malaria 
alongside molecular testing to detect parasites are cur-
rently considered to be most appropriate metrics in areas 
of low transmission and under elimination [3, 9].
In Iran, a national strategic plan for the elimination 
of malaria was approved by High Council for Health 
and Food Security in 2010 to stop local transmission by 
2025. In this regard, Iran achieved a substantial decline 
in malaria incidence according to WHO Malaria Reports 
[1, 10]. The burden of malaria decreased gradually from 
nearly 97,000 cases in 1991 to 16,000 in 2007 [Center for 
Diseases Management and Control (CDMC), Tehran, 
Iran, unpublished data]. A further reduction was reported 
in 2014 with 1251 being the total number of cases (75 % 
decrease since 1991). Iran is considered to be in the elimi-
nation phase for malaria since 2009 [11]. Areas of malaria 
transmission are found in the southern part of the coun-
try, which accounts for more than 90 % of the total number 
of cases [12]. The majority of cases, 70 % in 2014 (CDMC, 
Tehran, Iran, unpublished data), is due to imported cases 
from neighbouring Pakistan and Afghanistan [13].
Investigating the application of different metrics in 
order to demonstrate the absence of transmission and 
simultaneously show the likelihood of success and out-
comes of malaria interventions during pre-elimination 
and elimination programmes is essential in Iran. Previ-
ous serological studies in Bashagard and Ghale-Ganj 
Districts, southern Iran, found seroprevalence to Plas-
modium vivax and Plasmodium falciparum to be 1 % or 
less [12, 14]. No parasite carrier was detected by micros-
copy and/or molecular testing. Although seroprevalence 
was low in these districts, higher transmission patterns 
in neighbouring Sistan and Baluchistan Province are to 
be expected, based on previous incidence data [1]. This 
study was designed to determine serological and para-
sitological transmission levels of P. vivax and P. falcipa-
rum malaria in Chabahar District, Sistan and Baluchistan 
Province in the malaria elimination phase in southeast-
ern Iran.
Methods
Study areas and sample collection
This cross-sectional study was performed in Chabahar 
District, Sistan and Baluchistan Province in the southeast-
ern part of Iran in March 2012 (Fig. 1). Based on the 2014 
available census the total population of Chabahar city was 
120,000 with a total approximate population of 200,000 in 
the county of Chabahar. In these areas, both P. falciparum 
and P. vivax exist; however, P. vivax is the dominant spe-
cies with more than 88 % malaria infection cases (CDMC, 
Iran, unpublished data, 2014). The malaria cases reported 
in Iran was 3239 in 2011, 1629 cases in 2012 and 1387 in 
2013 [15, CDMC, Tehran, Iran, unpublished data]. In this 
area, most of the patients are adults and they may experi-
ence several infections by P. falciparum and P. vivax; how-
ever, there is no record of severe cases or deaths due to 
malaria (CDMC, Tehran, Iran, unpublished data). In this 
study, participants were selected from 64 different geo-
graphical clusters, (previously described endemic areas 
based on malaria incidence data [1]) in Chabahar city and 
surrounding villages. In Chabahar city participants were 
selected from 32 clusters targeting hot spots areas based 
on reported malaria case data. In rural areas 32 villages 
were selected across four groups: high (n = 10), moder-
ate (n = 8), low (n = 6) and absent (n = 8) malaria cases 
during the year 2011. In each cluster, 24 subjects were 
selected evenly from both sexes and from four age groups 
(<5, 6–15, 16–45, >45 years old), using systematic random 
sampling methods.
Demographic (e.g., age, gender, travel history, use of 
long-lasting insecticide nets (LLIN) and household infor-
mation (e.g., wall and ceiling structures) were obtained 
using a structured questionnaire, and measured axillary 
temperatures over 37.5  °C were recorded. Information 
on history of malaria infection was obtained through the 
questionnaire and confirmed by local healthcare docu-
ments. During house visits, entomologists examined any 
water source around the house that could be a poten-
tial larval breeding site for the presence of egg, larvae or 
pupae of Anopheles mosquito species. Houses located 
within 100 m of a larval breeding site were recorded. Fin-
ger-prick blood samples were obtained from each partici-
pant for microscopy smears as well as filter-paper blood 
spots, and the latter were stored at −20 °C with desiccant 
until processing. Blood slides were taken back to health 
centres and read by a malaria microscopy expert and in 
case individuals tested positive, they were treated through 
direct observed treatment by health workers at home.
Assessment of parasite carriage by microscopy 
and nested‑polymerase chain reaction
Thick and thin blood smears were considered negative if 
no parasites were observed after examining 200 fields of 
Giemsa-stained thick blood smears or by counting 1000 
red blood cells in thin blood smears at 1000× magnifica-
tion by an expert microscopist. To increase the sensitivity 
of parasite detection, all obtained results by microscopy 
were confirmed by nested polymerase chain reaction 
(nPCR). Briefly, two 3-mm spots were cut from filter 
papers using a puncher. The QIAamp® DNA Mini Kit 
(QIAGEN Inc, Valencia, CA, USA) was used to extract 
DNA according to the manufacturer’s instructions. P. 
vivax and P. falciparum was detected by nested-PCR 
amplification of the small sub-unit ribosomal ribonucleic 
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acid (18ssrRNA) genes. The nest-1 PCR was performed 
similarly for both Plasmodium species using primers 
described previously [16]. Amplification was carried out 
in a final volume of 25  µL including 1  µL nest-1 PCR 
product as a template. The cycling condition for nest-2 
PCR of P. vivax and P. falciparum corresponding genes 
was as follows: 95  °C for 5  min, 25 cycles of 94  °C for 
1 min, 58 °C for 1 min, 72 °C for 1 min followed by 72 °C 
for 15 min. Positive control samples, as well as three neg-
ative controls, were included in each set of amplification 
reactions. All products were visualized in 2  % agarose 
gels containing ethidium bromide under ultraviolet tran-
sillumination (UVItec, Cambridge, UK).
Assessment of anti‑malarial antibody responses
Blood spots were reconstituted as previously described 
and the solution was equivalent to a 1:100 dilution of 
whole blood or a 1:200 dilution of serum [17]. Anti-
body responses against apical membrane antigen-1 or 
the 19  kDa fragment of merozoite surface protein-1 for 
P. vivax (PvAMA-1 and PvMSP-119, respectively) and P. 
falciparum (PfAMA-1 and PfMSP-119) were determined 
by ELISA as previously described [17]. Briefly, sera sam-
ples were added in duplicate at a final concentration of 
1:1000 for MSP-119 and 1:2000 for AMA-1. In addition, 
four blank wells and a five-fold dilution series (starting 
at 1:100 for AMA-1 and 1:50 for MSP-119) of an Afri-
can hyper-immune plasma pool (n  =  30) were added 
per plate. Optical density (OD) values were measured at 
490 nm with a microplate reader.
Statistical analyses
Duplicate ODs per individual were averaged, adjusted 
for background reactivity and normalized against the 
Fig. 1 Map of a Iran and surrounding countries, b Iran with capital Tehran (star) and c Sistan and Baluchistan Province with capitals Zahedan (star) 
and Chabahar District in black. In c Sistan and Baluchistan Province are indicated in dark grey, other provinces in Iran in mid grey and neighbouring 
countries Afghanistan and Pakistan in light grey
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positive control curve as previously described to adjust 
for plate variation [17]. All further statistical analyses 
were done in STATA version 14. Infants under 1 year of 
age were excluded to remove any influence of maternally 
derived antibodies [18]. Thresholds to define seropositiv-
ity for the separate antigens were calculated using a finite 
mixture model [19]. Individuals were defined as seroposi-
tive when their adjusted OD value would be greater than 
the mean of the lower Gaussian distribution plus three 
times the standard deviation.
Principal component analysis was used to combine 
the following variables reflecting socio-economic sta-
tus (SES) as previously described by Vyas et  al. [20]: 
house with cement walls, a plaster ceiling, connected 
to pipeline water, connected to electricity, ownership 
of a domestic animal, ownership of additional facilities 
(such as a TV/fan/car), and family size. Three levels of 
SES were created (low, middle, high) and this was done 
separately for those living in the city and those in the 
surrounding villages. Details on the distribution of these 
variables by SES status can be found in Additional files 1 
and 2.
Differences in continuous descriptive metrics between 
Chabahar city and surrounding villages were tested with 
the Wilcoxon Mann–Whitney test, while differences 
in proportions were tested with Chi squared tests. Dif-
ferences in proportions were adjusted for the clustered 
sampling using the svy command in STATA without 
weighting by cluster size. The reversible catalytic model 
was used to define the seroconversion rate (SCR) and to 
plot corresponding seroconversion curves while fitting 
age-adjusted seropositivity to P. falciparum or P. vivax 
using maximum likelihood [18]. The SCR is analogous 
to the force of infection and reflects the rate at which 
the population becomes seropositive. The presence of a 
change point in transmission was investigated during the 
same model, yet fitting two different SCRs in the same 
population. Profile likelihood plots were used to deter-
mine when the most likely time for change in transmis-
sion intensity occurred. The model with a change point 
was compared to the model without a change point using 
the likelihood ratio test and the model that fitted the data 
best was presented [19].
Logistic regression was used to identify the likelihood 
of seropositivity based on explanatory factors. Standard 
errors were adjusted to allow for the clustered sampling 
as described above. An adjusted model was also created 
for all explanatory factors. Using retrospective sample 
size calculation methods for serology, considering the 
approximate 750 samples per study setting, an SCR of 
0.004 with a 95  % confidence interval can be estimated 
with a width of 0.002 to 0.004 (equating to an entomo-
logical inoculation rate of 0.00–0.02) [21].
Results
General characteristics of the study population 
and parasite detection
Serum was successfully eluted and serologically tested 
for 1479 participants and they were evenly distributed 
between the city (744, 50  %) and surrounding villages 
(735, ~50  %). Median age (16  years, ranging 2–70 and 
15, ranging 2–78) were similar in the two studied set-
tings (P = 0.357, Table 2). Risk factors for malaria were 
unevenly distributed (Table  1): LLIN use was signifi-
cantly lower in the village compared to the city (24 vs 
68  %; P  <  0.001) and reported history of malaria was 
significantly higher (24 vs 10  %; P =  0.003). In the city, 
participants were more likely to live close to a mos-
quito-breeding site compared to villagers (89 vs 53  %; 
P =  0.001). All participants were parasite-negative both 
by microscopy and nPCR.
Trends in anti‑malarial antibody responses by age
To define any serological evidence of exposure to P. fal-
ciparum or P. vivax, seropositivity to species-specific 
AMA-1 and MSP-119 antigens was combined. Partici-
pants living in villages were more likely to show evidence 
of exposure to either species compared to city dwellers. 
In total, 15 % of villagers were seropositive for P. falcipa-
rum (109/735), while 13 % for P. vivax (95/735) and 4 % 
for both species (30/735). In the city, 11 % (78/744), 7 % 
(50/744) and 2 % (14/744) were seropositive, respectively 
(Table 2).
Table 1 General characteristics of  the study population 
in  Chabahar city and  surrounding villages, south-eastern 
Iran
All reported proportions are adjusted for clustering within enumeration areas
a Reported history of malaria over the past 10 years; confirmed by local health 
records
b Reported travel history 4 weeks prior to sampling
c Within a 100 m radius of the household
d More than ten houses within a 100 m radius of the household
e Within the last 2 weeks
Demographic data % (95% CI) P value
City (n = 744) Village (n = 735)
Median age (range) 16 (2–70) 15 (2–78) 0.357
Male 42 % (38–45) 51 % (44–57) 0.012
Fever (≥37.5 °C) – 0 % (0–1) 0.159
LLIN 68 % (56–78) 24 % (13–40) <0.001
History of malariaa 10 % (7–14) 24 % (18–31) 0.003
History of travelb 13 % (7–25) 5 % (3–8) 0.017
Breeding sitec 89 % (76–95) 53 % (37–69) 0.001
High population densityd 77 % (61–88) 49 % (34–64) 0.026
Visitor from endemic areae 12 % (5–23) 12 % (6–23) 0.906
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In the 333samples tested from children aged one to 
5  years only 18 were seropositive (P. falciparum 4/333, 
1  % and P. vivax 15/333, 5  %). In the city, 70  % (7/10) 
and 40  % (4/10) were seropositive to PvMSP-119 and 
PfAMA-1 antigens, respectively, while one of these sam-
ples showed seroreactivity to both antigens (Additional 
file 1). In the village, 100 % (8/8) and none was seroposi-
tive to P. vivax and P. falciparum antigens, respectively. 
Corrected OD values in these seropositive children never 
exceeded 0.410 and only two were positive for more 
than one of the tested antigens (2/18; 11 %). In addition, 
their corrected OD values were always in close proxim-
ity to the cut-off of the antigen that they tested positive 
for (Fig. 2). If a more conservative cut-off of five standard 
deviations plus the mean of the lower Gaussian distribu-
tion was used, only six out of the 18 children remained 
positive (33 %). The majority lived in villages (5/6) and all 
only remained positive for PvMSP-119 (Fig. 2; Additional 
file 2).
Only adults (>15 years old) were seropositive to more 
than two antigens. The majority of participants were 
positive to a single antigen: 84 % in the city (95 positive 
to one antigen/113 positives to any antigen) and 76  % 
in the village (132/173). Regarding positivity to multiple 
antigens, only one individual in the city (1/113; 1 %) and 
three in the villages (3/173; 2 %) were positive to all four 
antigens. Similarly, for three antigens, this was six in the 
city (6/113; 5 %) and two in the villages (2/173; 1 %).
Seroconversion curves are shown in Fig. 3. In the city 
a change point in P. falciparum transmission was seen 
at 21  years before sampling was done (P =  0.018) with 
a SCR of 0.004  year−1 (0.002–0.007) before the change 
point and 0.153 year−1 (0.019–1.249) after. Seropositivity 
to P. falciparum antigens among those under the age of 
21 years was 2 % (10/411) and for those aged 21 or over 
21  % (68/320). The SCR for P. vivax was 0.014  year−1 
(0.006–0.033). In the villages, a change point in P. falci-
parum transmission was also seen, but more recently at 
4 years before sampling (P = 0.039). The SCR before the 
change point was zero while after the change point it was 
0.012 year−1(0.007–0.019). Plasmodium falciparum sero-
prevalence was none for those under the age of 4  years 
(0/46) and 16  % for those aged four or older (109/687). 
Plasmodium vivax transmission was similar to that in the 
city: 0.013 year−1 (0.008–0.021).
Adjusted likelihood of seropositivity
Older age and lower SES were associated with P. falcipa-
rum seropositivity in the adjusted model, Table  3. The 
crude odd ratios (OR) of P. falciparum and P. vivax sero-
positivity for those living in a village compared to those 
living in the city were 1.49 (0.97–2.28, P  =  0.068) and 
2.06 (1.36–3.13, P  =  0.001), respectively. The increased 
trend for P. vivax positivity remained apparent in the 
adjusted model (OR 2.12, 1.23–3.67, P  =  0.009). In 
addition, for P. vivax, older age and reported history of 
malaria increased the likelihood of seropositivity signifi-
cantly in the adjusted model. For P. falciparum, only age 
and SES were significantly associated with seropositivity 
in the adjusted model.
Discussion
Iran is certified as an elimination area since 2009 [11] and 
only approximately 1250 clinical cases were reported in 
2014, of which the majority originated in the southeast-
ern part of the country (CDMC, Tehran, Iran, unpub-
lished data). As transmission reaches eliminating levels, 
identifying areas with remaining transmission or absent 
transmission requires new approaches. In this study, 
transmission levels of P. falciparum and P. vivax malaria 
Table 2 Anti-malarial seropositivity and seroconversion rates for participants in Chabahar city and surrounding villages, 
south-eastern Iran
Seropositivity and seroconversion rates (SCR) are presented for P. falciparum and P. vivax. If the best model to fit the age-adjusted seropositivity data was one with a 
change point in transmission, the SCR before the change point is indicated as λ1, while the SCR after the change point is indicated with λ2
a For 17 individuals age data was missing, therefore total numbers in the ‘all ages’ group differ slightly from those presented in the separate age categories
Prevalence,  % (n/N)
City Village
P. falciparum P. vivax P.f/P.v P. falciparum P. vivax P.f/P.v
1 to 5 2 (4/174) 4 (7/174) 1 (1/174) 0 (0/159) 5 (8/159) 0 (0/159)
6 to 15 3 (5/191) 7 (14/191) 1 (2/191) 8 (16/213) 9 (19/213) 1 (3/213)
>15 19 (69/368) 8 (29/368) 3 (11/368) 26 (92/357) 19 (67/357) 8 (27/357)
All agesa 11 (78/744) 7 (50/744) 2 (14/744) 15 (109/735) 13 (95/735) 4 (30/735)
SCR (λ) λ1: 0.004 (0.002–0.007) 0.014 (0.006–0.032) λ1: 0.000 (0.000–0.000) 0.013 (0.008–0.021)
(95 % CI) λ2: 0.154 (0.020–1.186) λ2: 0.012 (0.007–0.019)
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were determined in Chabahar city and surrounding vil-
lages, Sistan and Baluchistan Province in the malaria 
elimination phase in southeastern Iran. There was no 
parasitological or serological evidence of recent local 
transmission, indicated by both an absence of micro-
scopic or sub-microscopic (nPCR) infections, and weak 
or absent serological responses to either species in chil-
dren up to the age of 5 years.
None of the children up to the age of 5 years in the vil-
lages showed seropositivity to P. falciparum, and only 
four were found in Chabahar city (2  %). Their adjusted 
antibody levels as represented by OD values were invari-
ably low and close to the cut-off level, suggesting that 
they may not be related to recent infection or, given the 
age group, perhaps any infection. A number of alternative 
approaches are available to determine positivity thresh-
olds in antibody tests [22] and indeterminate ranges are 
a common feature in commercially available serological 
assays [23]. When more conservative threshold of five 
standard deviations plus the mean of the lower Gauss-
ian distribution was used none of the young children in 
the city was classified as seropositive. This suggests anti-
body responses in this age group were low and serologi-
cal evidence of exposure to P. falciparum malaria is weak. 
Regarding P. vivax, using the more conservative threshold 
for positivity, only six out of the 15 seropositive 1–5 years 
old children remained positive. Similarly, for adults, sero-
logical responses were considered to be weak as only a 
minority mounted multi-antigenic responses. Approxi-
mately 15  % of the seropositives in the city were posi-
tive for more than one antigen and 25 % in the villages. 
Recent studies have likewise reported no parasitological 
evidence of transmission and low seroprevalence in the 
neighbouring malaria-endemic provinces of Hormozgan 
Fig. 2 Distribution dot plot of antibody responses for children 1–5 years of age. Antibody levels are expressed as normalized OD values. Horizontal 
lines represent thresholds for seropositivity and are based on 3 (dashed lines) or 5 (solid lines) standard deviations (SD) plus the mean of the lower 
Gaussian distribution (see “Methods” section). Plots are divided by antigen: a PfMSP-119, b PfAMA-1, c PvMSP-119 and, d PvAMA-1. OD optical density, 
Pv P. vivax, Pf P. falciparum, AMA-1 apical membrane antigen 1, MSP-119 merozoite surface protein 1–19
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(Bashagard) and Kerman (Ghale-Ganj) [12, 14]. The 
detected lower overall seroprevalence in these studies is 
most likely due to lower levels of historical exposure. It 
is clear that for broader use of serological approaches in 
studies, regions and countries a standardized assay would 
be needed, such as those available in standardized anti-
malarial antibody detection assays for the screening of 
blood products [24]). Nevertheless, the presented data 
from parasitological and serological tests strongly sup-
port low or absent levels of recent malaria transmission 
in these settings in Chabahar District.
The best model for age of P. falciparum seroconver-
sion in Chabahar city was one with two forces of infection 
changing 21 years before sampling was done (P = 0.018). 
Seroprevalence in the city for individuals aged under 
the age of 21 was ten-fold lower compared to those aged 
21  years and older. The timing of this change, 1991, 
coincides with a previously described dramatic drop in 
malaria cases in the early 90 s, both nationwide [25] and 
in the southwestern part of the country [13]. An alterna-
tive, but not mutually exclusive explanation, is that this 
could reflect increased risk of exposure in older individu-
als (>21  years), for example due to more frequent travel 
to malaria-endemic areas in neighbouring countries (e.g., 
Afghanistan and Pakistan). In the villages, a change point 
was seen at 4  years before sampling was done (2008; 
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Fig. 3 Anti-malarial seroconversion curves for participants in Chabahar city and surrounding villages, southeastern Iran. A reversible catalytic model 
was fitted to age-adjusted seropositivity data using maximum likelihood to create seroconversion curves. Solid lines represent the fitted probability 
for being seropositive, dotted lines represent the 95 % confidence interval for these fits, and triangles represent the observed proportion of seroposi-
tives per age decile. Seroconversion rates (SCR; λ) are presented on the graph. If the best model to fit the age-adjusted seropositivity data was one 
with a change point in transmission (see “Methods” section; Table 2), both SCRs are presented on the graph. The P. falciparum SRRs for the city and 
the village settings were 0.057 year−1 (0.034–0.094) and 0.010 year−1 (0.002–0.062), while for P. vivax these were 0.145 year−1 (0.049–0.423) and 
0.048 year−1 (0.022–0.103)
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P  =  0.039) suggesting transmission has only declined 
recently in these areas.
This might be explained by the up-scaling of different 
interventions during elimination strategies (CDMC, Teh-
ran, Iran, unpublished data), such as active case detection, 
case management, early diagnosis, prompt and effec-
tive treatment [artemisinin combination therapy (ACT) 
plus single dose of primaquine on day 3 as the first-line 
recommended therapy for P. falciparum uncomplicated 
malaria and chloroquine with 8  weeks primaquine for 
radical treatment of P. vivax], indoor residual spraying, 
the distribution of LLINs, larviciding, and improved 
diagnostic capacities in health facilities (microscopy and 
rapid diagnostic testing) [26]. In addition, Iran is working 
to improve its cross-border collaborations and to apply a 
malaria early warning system and outbreak preparedness 
plan for epidemics by increasing training of microsco-
pists, rural malaria mobile teams, and community volun-
teers to overcome this problem [27].
Moreover, no change in SCR was seen for P. vivax, with 
values similar in both rural and urban settings. This may 
be due to ongoing exposure to infection with this para-
site or boosting of antibody levels by hypnozoite-derived 
infections. However, it may also be due to small sample 
size in addition to low seroprevalence [28]. This requires 
further investigation.
The overall P. falciparum and P. vivax seroprevalence 
presented here (13 and 10 %, respectively) was lower than 
Table 3 Logistic regression analysis of explanatory factors for serological evidence of exposure to malaria
Confidence intervals were adjusted to allow for the clustered sampling
OR odds ratio, CI  confidence interval, LLIN long-lasting insecticide treated net
a Within a 100 m radius of household
b High: more than ten houses within a 100 m radius of household; low: less than ten houses within a 100 m radius of household
P. falciparum P. vivax
n/N Crude OR  
(95 % CI)
P value Adjusted OR  
(95 % CI)
P value n/N Crude OR  
(95 % CI)
P value Adjusted OR 
(95 % CI)
P value
Location
 City 78/744 1 0.068 1 0.405 50/744 1 0.001 1
 Village 109/735 1.49 (0.97–2.28) 1.27 (0.71–2.26) 95/735 2.06 (1.36–3.13) 2.12 (1.23–3.67) 0.009
Age
 1 to 5 4/333 1 0.009 1 0.020 15/333 1 0.032 1
 6 to 
15
21/404 4.51 (1.50–13.59) <0.001 5.00 (1.31–19.16) <0.001 33/404 1.89 (1.06–3.36) <0.001 1.72 (0.88–3.39) 0.110
 >15 161/725 23.48 (8.65–63.76) 22.17 (6.37–77.08) 96/725 3.24 (1.89–5.54) 2.55 (1.34–4.82) 0.006
LLIN use
 No 112/804 1 0.143 1 0.585 83/804 1 0.544 1
 Yes 73/669 0.76 (0.52–1.10) 1.13 (0.71–1.81) 62/669 0.89 (0.60–1.32) 1.07 (0.60–1.92) 0.820
Reported history of malaria
 No 129/1220 1 <0.001 1 0.156 101/1220 1 <0.001 1
 Yes 57/246 2.55 (1.62–4.00) 1.49 (0.85–2.60) 43/246 2.35 (1.71–3.22) 1.58 (1.10–2.28) 0.015
Breeding sitea
 No 68/431 1 0.029 1 0.969 49/431 1 0.196 1
 Yes 119/1046 0.69 (0.49–0.96) 1.01 (0.49–2.10) 95/1046 0.78 (0.53–1.15) 1.10 (0.59–2.06) 0.753
Population densityb
 Low 68/455 1 0.054 1 0.263 49/455 1 0.276 1
 High 83/763 0.69 (0.48–1.01) 0.83 (0.59–1.16) 65/763 0.77 (0.48–1.24) 0.97 (0.61–1.56) 0.901
Visitor from endemic setting
 No 161/1305 1 0.340 1 0.915 132/1305 1 0.269 1
 Yes 26/173 1.26 (0.78–2.03) 0.97 (0.50–1.86) 13/173 0.72 (0.40–1.30) 0.53 (0.24–1.18) 0.114
SES
 Low 80/506 1 0.122 1 0.011 47/506 1 0.969 1
 Mid-
dle
64/521 0.75 (0.51–1.09) 0.004 0.59 (0.40–0.88) 0.002 48/521 0.99 (0.63–1.57) 0.430 1.00 (0.58–1.74) 0.998
 High 39/412 0.56 (0.38–0.81) 0.47 (0.31–0.73) 46/412 1.23 (0.73–2.07) 1.26 (0.72–2.20) 0.406
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previously described levels in other countries in the East-
ern Mediterranean region, such as Somalia (18 and 19 %) 
[6], Djibouti (32 and 3  %, adults only) [29], and Yemen 
(32 and 3 %, children only) [30]. These studies took place 
between 2002 and 2011, while the data presented here 
are from 2012. The differences in seroprevalence are 
likely to be related to the lower level of transmission in 
Iran in recent years. Increasing collection of serological 
data in the region, alongside other metrics of malaria, has 
the potential to help in further characterizing regional 
transmission patterns.
As no parasite infections were detected with either 
microscopic or nPCR methods, risk factors to describe 
exposure to malaria could only be examined using sero-
logical outcomes. The increased likelihood of seroposi-
tivity to P. vivax remained twice as high for villagers in 
comparison with city dwellers in the adjusted model. It 
seems that ‘previous’ P. vivax transmission was higher 
in the villages surrounding Chabahar city than in the 
city itself, indicating higher potential receptivity for the 
re-introduction of malaria in the villages in this district. 
More geospatially explicit work would allow specific tar-
geting of these areas to make their use more cost-efficient 
[31]. Iran has several intervention policies in place, such 
as the distribution of bed nets free of charge since 2005 
[10], vector control strategies (such as microbial larvicid-
ing), as well as active case detection, case management, 
artemisinin-based combination therapy as the first-line 
recommended therapy for P. falciparum uncomplicated 
malaria, and improved diagnostic capacities. These could 
help maintain the absence or prevent the re-introduction 
of malaria transmission in the study areas with very active 
human population movements between Iran, Afghani-
stan and Pakistan, common parasite-vector fauna, as well 
as similar economic-cultural inhabitants, which provides 
an environment that is in favour of parasite transmission. 
Further monitoring of seroprevalence in residents of the 
study areas is considered highly useful given the low lev-
els of transmission and population movement between 
malaria-endemic areas of Pakistan and Afghanistan that 
might affect transmission in these settings.
Interestingly, SES influenced the trend for seropositiv-
ity to P. falciparum, but not P. vivax. This observation 
might be due to P. vivax antibody levels being predomi-
nantly associated with relapses rather than new infec-
tions, as recently described in Papua New Guinea [32], 
and thus not influenced by household characteristics. 
The shown similarity in P. vivax (but not P. falciparum) 
seroconversion curves between city and village settings 
as well as the fact that there was weak to absent parasi-
tological or serological evidence of recent P. vivax trans-
mission in children, support this hypothesis. However, 
the latter may also be due to a higher risk of P. vivax in 
older individuals (e.g. due to work). It would be useful 
to confirm these findings in other P. vivax endemic, but 
eliminating, areas. These assumptions would be strength-
ened by inclusion of a broader range of antigens, ideally 
including those related with hypnozoite carriage (as yet 
unidentified).
Conclusion
This study aimed to determine malaria transmission pat-
terns in Chabahar District, southeastern Iran. As ento-
mological endpoints are challenging to define correctly 
at very low transmission levels [4, 33], the study focussed 
on parasitological endpoints as well as serological meas-
ures, which are considered most appropriate in elimina-
tion settings [3, 9]. Firstly, the study found no evidence of 
recent transmission indicated by the fact that no parasite-
carrying individuals were identified (by either micros-
copy or nPCR) and children showed weak or absent 
serological responses to either P. falciparum or P. vivax. 
Secondly, a change point in P. falciparum transmission 
in Chabahar city was detected that overlaps with a pre-
viously described dramatic drop in cases since the early 
1990s [13, 25]. Lastly, the study showed a higher level of 
recent P. vivax transmission compared to P. falciparum 
transmission based on the SCRs in both the city and vil-
lage settings. Whether these antibody responses reflect 
active transmission due to new infections or responses to 
relapse infections is unclear. The weak to absent evidence 
of recent malaria transmission in Chabahar District, even 
though this study targeted malaria prone areas, is prom-
ising in the context of elimination.
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